PuriCore Share Price (PURI)

0.00 0.00 (0.00%) delayed: 5:20AM GMT
Bid price 0.00 Open price 0.00
Ask price 0.00 Prev close 25.00
High price 0.00 Spread 0.00%
Low price 0.00 Volume 0

Register now for FREE live PuriCore share prices, PuriCore stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get PuriCore Level 2 Data, indepth research tools and investor commentary for PuriCore (PURI) and other London Stock Exchange equities.

PuriCore Share Price Chart

Advanced Charts >>

Register now for FREE PuriCore share price charts

PuriCore Share Price Information

Name PuriCore Epic PURI
Sector Health Care Equipment & Services ISIN GB00B3XBCR18
Activites PuriCore develops and commercializes proprietary products that safely, effectively, and naturally kill contagious pathogens including major public health threats—M.tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and Legionella. Our products generate hypochlorous acid, the same natural anti-microbial produced by the human body to fight pathogens. Hypochlorous acid is highly effective in killing all types of bacteria, viruses, and fungal spores. PuriCore's technology and solutions are used in a broad range of markets that depend upon controlling contamination, including endoscopy, food retail, foodservice, hospitality, institutional, and wound therapy. Our antimicrobial solution is deployed as soaks, sprays, mists, and in other forms to limit the spread of infectious disease. The patented technologies use a simple combination of water, salt, and electricity to produce the same powerful solution found in the human immune system. PuriCore's highly sophisticated processes and controls allow the production of these unique biocidal solutions with a variety of different chemical and microbiological properties for use in specific settings and applications. Index n/a

PuriCore Key Numbers

Latest Share Price (p) 0.00 Net Gearing (%) -55.95
Market Capitalisation (£m) 11.03 Gross Gearing (%) 10.19
Shares in issue (m) 50.14 Debt Ratio 0.00
P/E Ratio 0.76 Debt-to-Equity Ratio 0.00
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.11
Dividend Yield (%) 0.00 Price to book value 0.39
Dividend cover (x) 0.00 ROCE (%) -24.75
Earning per share (p) 29.00 EPS Growth (%) 323.08
52 week high / low 38.00 / 17.50 DPS Growth (%) n/a

PuriCore Director Deals

Dec.Date Type Director Pos No. of Shares
14/10/2015 BUY Daniel Hegglin NED 500,000
28/09/2015 BUY Charles Spicer CH 77,922
28/09/2015 BUY Daniel Hegglin NED 500,000
02/04/2015 BUY Charles Spicer CH 50,610
12/08/2014 BUY Michael Ashton RES 50,000

More PuriCore Director Deals >>

PuriCore Company News

07:43 08/02/2016

PuriCore's revenue

PuriCore said 2015 group revenue was USD23.4m, up 36.5% from USD17.1m, driven by Supermarket Retail revenue growth. It added that year-end net cash of USD15.5m reflected continued disciplined investment. "In light of the compelling opportunities to potentially generate significant shareholder...

07:13 08/02/2016

FLASH: PuriCore reports surge in FY revenue

Story provided by StockMarketWire.com

07:00 08/02/2016

Strategic Review and Trading Update

/* */ RNS Number : 3118O PuriCore Plc 08 February 2016   PuriCore plc ("PuriCore" or the "Company")   A specialty biopharmaceutical company: developing novel immunomodulatory therapies   8 February 2016 - PuriCore plc (AIM: PURI), an...

More PuriCore Company News >>

Register now for FREE PuriCore company news

PuriCore Share Price Discussions

10 months ago

PuriCore plc (PURI)

PuriCore specializes in developing and commercializing solutions to protect against the spread of infectious pathogens. Our proprietary products are effective while being completely safe for human and animal health and the environment. PuriCore has broad experience in key markets that...

more than 1 year ago

Puricore - US FDA approval and US Supermarket interest (PURI)

This one has come to my attention after a sudden surge from the bottom of its price range. In the last two weeks, PURI has announced US FDA approval to market its Sterilox Endoscopy High-Level Disinfectant System as a medical device in the US; also announced first prelims showing increasing...

Register now for FREE PuriCore share price discussions